Ibogaine Relapse Rates: Why No One Can Honestly Quote You a Number

Search for ibogaine relapse rates and you will find percentages quoted with remarkable confidence. Seventy percent still abstinent at one year. Eighty percent. Ninety. The numbers vary wildly between sources, which is the first clue that something is wrong with all of them.

This guide is an independent resource. We do not operate a clinic, we do not take referral fees, and we have no treatment outcomes to advertise. That puts us in an unusual position: we can tell you plainly that the honest answer to "what is the ibogaine relapse rate" is that nobody knows, and then explain why that is true, what the evidence does support, and what genuinely appears to influence whether people stay well.

Start with the size of the actual evidence base

On August 8, 2026, we queried the public ClinicalTrials.gov registry for every study registered with ibogaine as an intervention. The result was nine records total — the complete registered global footprint.

Of those nine, only four are interventional, meaning participants actually received ibogaine under study conditions. The other five are observational: researchers watched and measured people who obtained treatment independently.

The four interventional studies:

| Sponsor | Country | Condition | Enrollment | Status | |---|---|---|---|---| | University of São Paulo | Brazil | Alcoholism | 9 | Completed | | ICEERS | Spain | Methadone detoxification | 20 | Completed | | atai Therapeutics | United Kingdom | Opioid withdrawal | 116 | Completed | | Johns Hopkins University | United States | — | 0 | Withdrawn |

The Johns Hopkins entry was withdrawn before enrolling a single participant. So the entire completed interventional evidence base for ibogaine is roughly 145 people, across three trials, none of them conducted in the United States.

That is the foundation on which confident relapse percentages are being built. It does not support them.

Why 145 people cannot produce a reliable relapse rate

Three structural problems, any one of which would be disqualifying on its own.

The samples are tiny. A nine-person trial cannot generate a stable percentage. If one additional participant relapses, your "rate" swings by eleven points. Numbers derived from samples this small are noise wearing the costume of precision.

Trials of this kind are built to measure the wrong window. Detoxification and withdrawal studies are designed to answer whether the acute phase can be gotten through — whether withdrawal is suppressed, whether the protocol is tolerable. Relapse is a question about the following year, and it requires deliberate long-term follow-up that short trials are not structured to provide. A study can succeed completely at its own endpoint and tell you nothing about month nine.

The people who get counted are not a random sample. Ibogaine treatment is expensive, usually requires international travel, and demands enough stability to organize and survive the trip. That selects hard for motivation, financial resources, and social support — three of the strongest predictors of recovery outcomes regardless of what treatment is given. Any outcome figure drawn from that population is measuring the population as much as the intervention.

Add the reporting asymmetry that follows every treatment sold commercially: people who do well stay reachable and answer the follow-up call. People who relapse frequently disappear, and disappearance is not counted as failure. It is simply counted as missing.

What the evidence does support

None of this means ibogaine does nothing. It means the specific claim "X percent stay clean" is unsupported, while other claims are on firmer ground.

The consistent signal across the research and the clinical literature is that ibogaine can markedly reduce acute opioid withdrawal symptoms and that many people report a substantial drop in craving in the period immediately afterward. That is the finding trials were actually built to detect, and it is the finding that recurs.

What that describes is an interruption, not a cure. The distinction is the single most important thing to understand before treatment, because it determines what you do next.

Understanding what ibogaine is and how it acts on the brain makes the interruption model easier to grasp: the compound and its long-lived metabolite appear to reset certain signalling patterns and open a window in which cravings are quieter and behaviour is less automatic. The window is real. It is also temporary.

The window is the whole story

Nearly every account of relapse after ibogaine follows a recognisable shape. Treatment goes well. Withdrawal is far milder than expected. Craving drops away, sometimes completely, and the absence is so total that it feels permanent. It is not.

Over the following weeks and months, ordinary life resumes — the same city, the same relationships, the same stressors, in many cases the same phone with the same contacts in it. Craving returns gradually rather than suddenly, and the gap between "I feel completely fine" and "I am using again" can close without any dramatic moment to mark it.

The failure mode is not that ibogaine wore off. It is that the window was treated as the finish line instead of the opening.

This is why practitioners who take outcomes seriously treat aftercare and integration as the substantive part of the process rather than an afterthought, and why the first ninety days after treatment matter disproportionately. The period when cravings are quiet is precisely the period in which new structure can be built with the least resistance — and it is the period most often wasted, because nothing feels urgent.

There is a further hazard specific to opioids that must be stated directly.

Critical safety warning: Ibogaine treatment substantially reduces opioid tolerance. Returning to a previously normal dose after treatment can be fatal. Post-ibogaine relapse carries a genuine and documented overdose risk, and this is not a theoretical concern. Anyone leaving treatment should have naloxone available, should never use alone, and should treat any return to use as a medical emergency in the making.

What appears to actually predict staying well

Since the percentages are unreliable, the more useful question is what distinguishes people who hold their gains from people who do not. Across the clinical literature and practitioner reporting, the same factors recur — and notably, almost none of them are about the dose.

Whether anything was arranged in advance. People who arrive with therapy scheduled, housing sorted, and a return plan already in place do better than people who intend to figure it out afterward. Intentions formed during the euphoric post-treatment period are unreliable; arrangements made beforehand are not.

Whether the environment changed. Returning to the same house, the same supply, and the same social circle puts enormous weight on willpower during the exact period when the sense of invulnerability is highest.

Whether underlying conditions were addressed. Substance use frequently sits on top of untreated trauma, depression, or chronic pain. An interruption that leaves the driver untouched is an interruption waiting to end. This is why the interaction between substance use and conditions like depression, anxiety, and PTSD deserves attention as part of planning rather than afterwards.

Whether the person had continuing support. Ongoing contact with a therapist, a group, or a structured programme is the most consistently protective factor in addiction outcomes generally, and there is no reason to expect ibogaine to be the exception.

Whether expectations were calibrated. People told they were cured tend to do worse than people told they had been given a head start. Believing the problem is solved removes the motivation to do the work that keeps it solved.

How to evaluate a clinic's relapse claims

You can use all of the above as a screening tool. When a provider quotes you an outcome figure, ask four questions:

1. How many people is that based on? A percentage without a denominator is not a statistic.
2. How long were they followed, and by whom? Self-reported check-ins at thirty days are not one-year outcomes.
3. How many were lost to follow-up, and how are they counted? If non-responders are excluded rather than counted as unknown, the figure is inflated by construction.
4. Is it published or verifiable anywhere? If the number exists only in marketing material, treat it as marketing material.

A provider who responds to those questions with candour — "our follow-up is informal, here is what we actually know, here is what we do not" — is demonstrating something more valuable than a high percentage. A provider who repeats the number more insistently is telling you what you need to know.

The same logic applies to screening in the other direction. Ibogaine carries documented cardiac risk, and rigorous medical screening and safety protocols are non-negotiable regardless of any outcome claims. A clinic quoting exceptional success rates while screening casually is not a clinic with better results. It is a clinic with weaker filters.

The honest summary

Ibogaine appears to do something real and unusual for opioid withdrawal and craving in the acute period. The registered research base supporting it is small, geographically concentrated outside the United States, and finished — with the sole American interventional trial withdrawn before it began. No credible long-term relapse rate exists, and anyone quoting you one with confidence is either repeating something they have not examined or selling something.

What the evidence supports is narrower and more useful: treatment can open a window. What happens in that window — whether structure gets built, environment changes, underlying conditions get treated, support continues — appears to matter far more to the outcome than anything about the treatment itself.

If you are weighing this decision, our overview of the current state of ibogaine research covers the studies in more detail, and our walkthrough of what the treatment process involves sets out what to expect and what to arrange in advance.

Plan for the window. Not for the miracle.

---

Medical disclaimer: This article is educational and independent. It is not medical advice, and this site is not a treatment provider and is not affiliated with any clinic. Ibogaine carries documented cardiac risks, including QT interval prolongation and reports of fatalities, and requires comprehensive cardiac and medical screening under supervision. It is a Schedule I substance in the United States and is not legally available for treatment there. Never discontinue prescribed medication without medical guidance. Consult a qualified physician before making any treatment decision.

Overdose risk after treatment: reduced tolerance following ibogaine makes relapse potentially fatal. Carry naloxone. Do not use alone.

If you are in crisis: call or text 988 (Suicide & Crisis Lifeline, U.S.) for free, confidential, 24/7 support. For substance use treatment referrals, SAMHSA's National Helpline is 1-800-662-4357.